The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations

Antiviral Therapy

Volumn 11, Issue 2, 2006, Pages 155-163

  White, Kirsten L ^a   Chen, James M ^a   Feng, Joy Y ^b   Margot, Nicolas A ^a   Ly, John K ^a   Ray, Adrian S ^a   MacArthur, Holly L ^a   McDermott, Martin J ^a   Swaminathan, S ^a   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

^b GILEAD SCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; TENOFOVIR; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; MOLECULAR MODEL; MUTATION; NONHUMAN; PHENOTYPE; POLYMERIZATION; PRIORITY JOURNAL;

CELL LINE; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; MUTATION; PHENOTYPE; PROTEIN BINDING; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 33645500469     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246:1155-1158.
2. Lin P-F, Samanta H, Rose RE, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170:1157-1164.
3. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997; 41:1094-1098.
4. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87-94.
5. Garcia-Lerma JG, MacInnes H, Bennett D, et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 2003; 77:5685-5693.
6. Winters MA, Shafer RW, Jellinger RA, et al. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997; 41:757-762.
7. Gu Z, Gao Q, Fang H, et al. Identification of a mutation of codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′- dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994; 38:275-281.
8. White KL, Margot NA, Wrin T, et al. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002; 46:3437-3446.
9. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate in antiretroviral-experienced patients. J Infect Dis 2004; 189:837-846.
10. McColl DJ, Margot NA, Cheng AK, Miller MD. Development of K65R versus thymidine analog-associated mutations (TAMS) in antiretroviral-treated patients. Sixth International Congress on Drug Therapy in HIV Infection. November 17-21 Glasgow, UK. Abstract 112.
11. Parikh U, Koontz D, Sluis-Cremer N, et al. K65R: A multi-nucleoside resistance mutation of increasing prevalence exhibits bi-directional phenotypic antagonism with TAM. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11 San Francisco, Calif, USA. Abstract 54.
12. Bazmi HZ, Hammond JL, Cavalcanti SCH, Chu CK, Schinazi R, Mellors JW. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 2000; 44:1783-1788.
13. Lanier ER, Givens N, Stone C, et al. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med 2004; 5:394-399.
14. Elion R, Cohen C, DeJesus E, et al. COL40263: Resistance and efficacy of once-daily trizivir and tenofovir DF in anti-retroviral naïve subjects. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11 San Francisco, Calif, USA. Abstract 53.
15. Naeger LK, Miller MD. Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out? Curr Opin Investig Drugs 2001; 2:335-339.
16. Goldschmidt V, Marquet R. Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol 2004; 36:1687-1705.
17. White KL, Margot NA, Ly JK, et al. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 2005; 19:1751-1760.
18. Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 1999; 179:92-100.
19. Boucher CAB, Keulen W, van Bommel T, et al. HIV-1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996; 40:2404-2409.
20. Cherrington JM, Fuller MD, Mulato AS, et al. Comparative kinetic analysis of interation of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases. Antimicrob Agents Chemother 1996; 40:1270-1273.
21. Kati WM, Johnson KA, Jerva LF, Anderson KS. Mechanism and fidelity of HIV reverse transcriptase. J Biol Chem 1992; 267:25988-25997.
22. White KL, Chen JM, Margot NA, et al. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother 2004; 48:992-1003.
23. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci U S A 1998; 95:13471-13476.
24. Meyer PR, Matsuura SE, Schinazi RF, So AG, Scott WA. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob Agents Chemother 2000; 44:3465-3472.
25. Traut T. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994; 140:1-22.
26. Gao W-Y, Cara A, Gallo RC & Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A 1993; 90:8925-8928.
27. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998; 282:1669-1675.
28. Tuske S, Sarafianos SG, Clark AD, et al. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol 2004; 11:469-474.
29. Chen JM, Jin G, Sung A, Levin JI. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1′ groups. Bioorg Med Chem Lett 2002; 12:1195-1198.
30. Hagler AT, Osguthorpe DJ, Dauber-Osguthorpe P, Hempel JC. Dynamics and conformational energetics of a peptide ormone: vasopressin. Science 1985; 227:1309-1315.
31. Dykes DC, Friedman FK, Dykes SL, Murphy RB, Brandt-Rauf PW, Pincus MR. Molecular dynamics of the H-ras gene-encoded p21 protein; identification of flexible regions and possible effector domains. J Biomol Struct Dyn 1993; 11:443-58.
32. Wilson JE, Porter DJT, Reardon JE. Inhibition of viral polymerases by chain-terminating substrates: a kinetic analysis. In Methods of Enzymology, vol. 275; pp. 398-424. Edited by Kuo LC, Olsen DB and Carroll SS. San Diego: Academic Press, Inc.
33. Deval J, White KL, Miller MD, et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004; 279:509-516.
34. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999; 4:35-43.
35. Tong W, Lu C-D, Sharma SK, Matsuura S, So AG & Scott WA. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Biochemistry 1997; 36:5749-5757.
36. Hauschka PV. Analysis of nucleotide pools in animal cells. Methods Cell Biol 1973; 7:361-462.
37. Ray AS, Murakami E, Basavapathruni A, et al. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 2003; 42:8831-8841.
38. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001; 75:4832-4842.
39. Ueno T, Mitsuya H. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2′,3-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry 1997; 36:1092-1099.
40. Gu Z, Fletcher RS, Arts EJ, Wainberg MA, Parniak MA. The K65R mutant reverse transcriptase of HTV-1 cross-resistant to 2′,3′- dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J Biol Chem 1994; 269:28118-28122.
41. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37:15908-15917.
42. Naeger LK, Margot NA, Miller MD. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002; 46:2179-2184.
43. Lennerstrand J, Hertogs K, Stammers DK, Larder BA. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol 2001; 75:7202-7205.
44. Sluis-Cremer N, Arion D, Parikh U, et al. The 3′-azido group is not the primary determinant of AZT responsible for the excision phenotype of AZT-resistant HIV-1. J Biol Chem 2005; 280:29047-29052
45. Meyer PR, Smith AJ, Matsuura SE, Scott WA. Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase. J Biol Chem 2004; 279:45389-45398.
46. Boyer PL, Imamichi T, Sarafianos SG, Arnold E, Hughes SH. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision. J Virol 2004; 78:9987-9997.
47. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 2001; 6:115-126.
48. Meyer PR, Matsuura SE, Zonarich D, et al. Relationship between 3′-azido-3′-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants or human immunodeficiency virus type 1 reverse transcriptase. J Virol 2003; 77:6127-6137.
49. Hsieh JC, Zinnen S, Modrich P. Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J Biol Chem 1993; 268:24607-24613.
50. Dahlberg ME, Benkovic SJ. Kinetic mechanism of DNA polymerase I (Klenow fragment): identification of a second conformational change and evaluation of the internal equilibrium constant. Biochemistry 1991; 30:4835-4843.
51. Sluis-Cremer N, Arion D, Kaushik N, Lim H, Parniak MA. Mutational analysis of Lys65 of HIV-1 reverse transcriptase. Biochem J 2000; 348:77-82.
52. Shah FS, Curr KA, Hamburgh ME, et al. Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem 2000; 275:27037-27044.